Adalimumab Level for Rheumatic Diseases
Also known as: TNF inhibitor antibody, Anti-TNF inhibitor antibody, Anti-TNF-alpha Drug, TNF alpha antibody, Humira® anti-drug antibody
Use
This test measures the concentration of the TNF-α inhibitor adalimumab in serum to assist in evaluating therapeutic levels for individuals with rheumatic diseases. It is intended to help differentiate between treatment failure due to pharmacokinetic factors (e.g., subtherapeutic drug levels) versus pharmacodynamic issues, informing decisions such as dose adjustment or switching therapies.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Immunoassay (ELISA)
Biomarkers
Adalimumab
Analyte
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
0.5 mL
Container
red-top tube (no gel)
Collection Instructions
Serum collected in a red-top tube (no gel). Draw blood just before next infusion.
Patient Preparation
Refrain from biotin supplements or biotin-containing vitamins 24–48 hours before draw (when performed with anti-drug antibody assay).
Causes for Rejection
Serum separator tube (SST); gross hemolysis.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 7 days |
| Frozen | -20°C: 8 months; -70°C: 90 days |
Other tests from different labs that may be relevant